Pharma News

After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two ongoing Phase 3 clinical trials tes...

The FDA has approved Aqneursa as an oral treatment for neurological symptoms associated with Niemann-Pick disease type C, a rare genetic disease, in adults and children weighing at least 15 kg, accord...

Biomea Fusion’s stock is on the up after the company plans to resume two clinical trials evaluating its therapy for type 1 (T1D) and 2 diabetes (T2D) after the US Food and Drug Admin...

The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.

Some counterfeits contain bacteria and have high impurity levels or different chemical structures to FDA-approved medicines.

Boehringer Ingelheim has opened a €60m ($66.8m) research building in Vienna, Austria, as the company looks to double down in the oncology therapeutics space. The building is named after Ange...

U.S. Food and Drug Administration approved osimertinib (Tagrisso) for adults with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) who have not experienced d...

A new study details how a nasal spray formulated by investigators from Brigham and Women's Hospital may work to protect against viral and bacterial respiratory infections. Based on their preclinic...

Researchers find that the antidepressant vortioxetine may offer new hope for glioblastoma patients by crossing the blood-brain barrier and significantly reducing tumor size in preclinical models.

The US Food and Drug Administration (FDA) has granted fast-track designation to narmafotinib, Amplia Therapeutics’ lead drug for the treatment of advanced pancreatic cancer. In the future, n...

A new gene therapy ATSN-101 has restored vision in patients with Leber congenital amaurosis type I (LCA1), a rare genetic condition causing blindness. In a small trial, those receiving the hig...

GSK PLC on Friday announced positive headline results of the Matinee phase III clinical trial evaluating Nucala.